DECKTHERAPEUTICS - Key Persons
Job Titles:
- Leader
- Member of the Scientific Advisory Board
- Clinical Advisor
Dr. Mangum is a leader in pediatric clinical pharmacology and drug development. He has been instrumental in developing multiple compounds for the care of children worldwide. His expertise is in neonatal pharmacology where he has excelled in understanding the pharmacology and pathophysiology of disease in the most vulnerable patients, the neonate. He also has served as an academic with appointments in the Schools of Medicine at Duke University and University of North Carolina-Chapel Hill as Associate Clinical Professor, Clinical Pharmacology and Associate Clinical Professor, Pediatrics. He is a graduate of The Medical University of South Carolina where he received his Doctorate in Pharmacy with special thesis emphasis on neonatal/pediatric pharmacology. Currently, Dr. Mangum is a co-founders and CEO of a pediatric CRO, Paidion Research, Inc. dedicated to the excellence in pediatric clinical research.
Job Titles:
- Chairman
- Chairman of the BOARD of DIRECTORS
Dan Deckelbaum MD CM, MPH, FRCS(C), is the co-director and founder of the Centre for Global Surgery and a critical care physician, trauma and acute care surgeon at the McGill University Health Centre (MUHC). He is on faculty at the Divisions of Trauma and General Surgery at the McGill University and associate member of the Department of Epidemiology, Biostatistics and Occupational health at McGill University. He obtained his subspecialty training in trauma surgery and critical care at Jackson Memorial Hospital in Miami. During his fellowship he completed a Masters of Public Health at the University of Miami. In addition to his passion for clinical practice, he has specific expertise in health system development, spearheading programs across the globe (in partnership with United Nations Institute for Training and Research, Red Cross movement, and governments in North America, Europe, Africa and Asia) to develop pre-hospital systems, augment critical care infrastructure, as well as advance critical care transport systems. Dr. Deckelbaum is the assistant medical director of the Montreal Canadiens Hockey Club. With his highly acclaimed clinical achievements, Dr. Deckelbaum has important expertise in the therapeutics of traumatic brain injury as well as ischemic and reperfusion injuries. Dr. Deckelbaum has received numerous awards and recognitions including Grand Challenges Canada.
Job Titles:
- Member of the Scientific Advisory Board
- DISTINGUISHED PROFESSOR of NEUROLOGY and PEDIATRICS, UCSF
Donna Ferriero, MD MS is a Distinguished Professor of Neurology and Pediatrics at UCSF. She is also a member of the Biomedical Sciences Graduate Program and the Weill Institute for Neurosciences. Dr. Ferriero is Director of the Neonatal Brain Disorder Laboratories and co-director of the Newborn Brain Research Institute at UCSF. Her laboratory has been critical in defining the relationship of selectively vulnerable populations of neural cells during maturation-dependent injury. She received the UCSF Chancellor's Award for the Advancement of Women and the Maureen Andrew Mentor Award from the Society for Pediatric Research. She is Past-President of the Child Neurology Society and the American Pediatric Society. She is the recipient of the 2000 Sydney Carter Award for excellence and leadership in Child Neurology, and was elected to the National Academy of Medicine in 2005. She received the Royer Award for Excellence in Academic Neurology in 2007 and the Willis Lecture for outstanding contributions to stroke research in 2010. She was elected to the Association of American Physicians in 2011 and to the American Academy of Arts and Sciences in 2013.
Job Titles:
- Member of the Scientific Advisory Board
- Chief of the Division of Neurocritical Care & Emergency Neurology
- CHIEF of the DIVISION of NEUROCRITICAL CARE & EMERGENCY NEUROLOGY, YALE SCHOOL of MEDICINE
Dr. Kevin Sheth is the founding Chief of the Division of Neurocritical Care & Emergency Neurology at Yale School of Medicine. His interests are in the advancement of therapies for devastating acute neurological syndromes, especially those complicated by brain ischemia, swelling and hemorrhage. He is a nationally recognized clinical and translational scientist and has directed several multicenter studies. In pioneering the development of new strategies to treat brain swelling, his work has changed the fundamental approach to brain injury in the ICU and spurned the creation of new technologies in drug delivery and neuroimaging. His team at Yale has served as a national model for academic critical care neurology units.
He is currently the principal investigator for two NIH neuroscience networks, NeuroNEXT and StrokeNet and three additional RO1/UO1 awards from the NIH. Dr. Sheth has served as PI or co-PI for 8 multicenter clinical trials in stroke, as well as chair for clinical endpoint and data safety monitoring committees for several pivotal studies. He is the winner of the prestigious Robert Siekert Award from the American Heart Association (AHA) and the Derek Denny Brown Award from the American Neurological Association. His research has been funded by the NIH, American Academy of Neurology, AHA, and the US Army. Dr. Sheth is the author of over 190 publications and has served on study sections for the NIH, AHA, FDA and NASA. He is an Associate Editor at Neurology and on the editorial boards for Stroke and Neurosurgery. His work has been showcased in The Washington Post, Wall Street Journal, NPR and CNN.
Finally, Dr. Sheth has formed exciting partnerships with entrepreneurs, pharmaceutical companies, and medical device start-ups to bring forward highly innovative solutions. These efforts have resulted in extensive knowledge of FDA pathways, development of phase I-III drug programs, and implementation of new technology into the clinical workspace. The principal theme of his efforts are towards collaboration and an improved understanding of neurological disease.
Job Titles:
- Member of the Leadership Team
- VP CMC
Dr. Marc Willuhn has more than 20 years' experience in the pharmaceutical and biotech industry. Previously, Dr. Willuhn was VP R&D at Fresenius Kabi and Head of the Innovation & Development Centre in Uppsala, Sweden, and Director of Process Development at Baxter Healthcare in Brussels, Belgium. During this time, he was involved in the registration of several new i.v. lipid emulsions in the US. Dr. Willuhn studied chemistry at Gerhard Mercator University in Germany and at McMaster University in Canada. He obtained his Ph.D. in organic chemistry at the Max Planck Institute for Coal Research in Germany and carried out post-doctoral research at the University Rene Descartes in Paris, France.
Job Titles:
- Member of the Scientific Advisory Board
- CLINICAL ADVISOR
- R & D Executive
Dr. Rebecca Juliano is a seasoned pharmaceutical R&D executive with scientific and development expertise in preclinical and clinical omega-3 fatty acid research. Most recently, Dr. Juliano served as the SVP of Clinical R&D at Amarin Pharma, where she led the Clinical Development/Operations and Biostatistics & Data Management teams who successfully completed the REDUCE-IT cardiovascular outcomes study with the omega-3 therapeutic Vascepa and actively supported global regulatory approvals. In an earlier role, Dr. Juliano supported the launch of the omega-3 therapeutic Omacor/Lovaza at Reliant Pharmaceuticals. Dr. Juliano earned a degree in Chemistry from the University of California at Santa Cruz, followed by an MA, MPhil, and PhD in Nutritional Biochemistry from Columbia University in New York City, and an American Heart Association fellowship for postdoctoral research at Weill Cornell Medical Center in New York City.
Job Titles:
- CHIEF EXECUTIVE OFFICER
- Executive
- Member of the Board of Directors
- Member of the Leadership Team
Dr. Soren Weis Dahl is a biotech executive whose career-long life science and business experience in the US and Europe includes various leadership positions in biotech and pharma, strategy and business development and biotech consulting. Most recently, Dr. Dahl was the CEO of the orphan drug start-up Prophylix and led the sale of the company's assets to the US orphan drug specialist Rallybio. One of Prophylix's former assets, RLYB211, is now Rallybio's lead project. Dr. Dahl received his M.Sc. in Chemical Engineering and PhD in protein chemistry from the Technical University of Denmark and his MBA from Copenhagen Business School.
Job Titles:
- ADVISOR
- Member of the Board of Directors
- Member of the Leadership Team
- NON - EXECUTIVE DIRECTOR
Dr. William Chin is the Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School (HMS). Dr. Chin is formerly EVP for Science and Regulatory Advocacy and CMO at Pharmaceutical Research and Manufacturers of America (PhRMA). He was the Executive Dean for Research at HMS and worked at Eli Lilly and Company last as Senior Vice President for Discovery Research and Clinical Investigation.
Dr. Chin is a Harvard-trained endocrinologist and longstanding faculty member. He was Chief of the Genetics Division in the Department of Medicine at Brigham and Women's Hospital, a Howard Hughes Medical Institute Investigator and Professor of Medicine at HMS. He has been honored with numerous awards for research, mentorship and leadership. Bill received his A.B. in Chemistry from Columbia University and his M.D. from HMS.
Job Titles:
- Member of the Scientific Advisory Board
Job Titles:
- Member of the Scientific Advisory Board
Job Titles:
- Member of the Leadership Team
- VP CHEMISTRY
Job Titles:
- Member of the Board of Directors
- BOARD OBSERVER
John Parker founded Springhood Ventures to back young companies solving the biggest problems in children's health. Springhood provides critical early investment and support to companies developing important life science and healthcare solutions for children. In parallel to this role, he established and manages the child health-focused program-related investment initiative of the Charles H. Hood Foundation, a Boston-based private foundation that supports pediatric research, where he also serves as a trustee.
In addition to Deck, Parker is an observer on the boards of SmolTap, Nicolette, Argus Cognitive, Anida Pharma, Mesentech, BioROSA Technologies, Prapela, and Aldatu Biosciences. He also serves on the advisory boards of multiple nonprofit entities, largely around pediatric health and mission-driven healthcare investing, and a number of pre-launch pediatric-focused startups. He is a frequent speaker on pediatric innovation, investment in child health solutions, and mission investing.
Previously, Parker spent 25 years in the alternative investment industry, including senior roles in venture capital, private equity, and hedge funds. Early in his career he worked in international merchant banking and has a BA from Dartmouth College and an MBA from Dartmouth's Tuck School of Business.
Job Titles:
- Member of the Scientific Advisory Board
- PROFESSOR of BIOSTATISTICS, MAILMAN SCHOOL of PUBLIC HEALTH, COLUMBIA UNIVERSITY
Ying Kuen (Ken) Cheung, PhD, is Professor of Biostatistics in the Mailman School of Public Health at Columbia University. His research interests focus on the development and evaluation of evidence-based treatments, interventions and policies at all phases of translational research. He is an expert in experimental designs, adaptive designs in clinical trials of treatments for cancer, stroke, neurological disorders, cardiovascular diseases, and mental health, SMART designs for behavioral intervention technologies, and N-of-1 personalized trials. He is a recipient of IBM Faculty Award on Big Data and Analytics. He is a Fellow of the American Statistical Association, and a Fellow of the New York Academy of Medicine.
Job Titles:
- Member of the Board of Directors
- NON - EXECUTIVE DIRECTOR
- Scientist
- Founder and Former Chairman and CEO of SomaLogic
Dr. Gold is an internationally recognized scientist whose research at the University of Colorado Boulder has spawned numerous discoveries and commercially successful biotechnology patents.
Dr. Gold is the Founder and former Chairman and CEO of SomaLogic. Prior to SomaLogic, he founded and was the Chairman of NeXagen, Inc., later NeXstar Pharmaceuticals, Inc., which merged with Gilead Sciences, Inc. in 1999. In 1981, Dr. Gold co-founded and served as co-director of research at Synergen, Inc. which was later acquired by Amgen, Inc.
Dr. Gold also serves on the board of directors of NASDAQ-listed 180 Life Sciences. He has been a member of the American Academy of Arts and Sciences since 1993 and was elected to the prestigious National Academy of Sciences in 1995.
Job Titles:
- PROFESSOR of PEDIATRICS in the FIELD of NEWBORN MEDICINE, HARVARD MEDICAL SCHOOL, BOSTON, USA
I am a dual boarded newborn medicine physician and child neurologist with my research focus in the newborn brain. My research work has been supported for over two decades by funding from both Foundations and Federal National institute of Health sources. As all our research activities are clinical investigations, our studies and clinical care of high-risk infants are tightly integrated. My research is targeted at understanding the timing, mechanisms and impact of cerebral injury and altered cerebral development in the human infant. Thus, my studies have focused on infants at high risk for brain injury including the prematurely-born infant, the sick term-born infant, and the infant with congenital heart disease. We aim to investigate means of accurate, early diagnosis of brain injury as well as developing treatments and preventive strategies to reduce brain injury and the related subsequent neurodevelopmental disabilities. This research work has utilized technologies including near infrared spectroscopy, electroencephalography and magnetic resonance imaging as well as now emerging new pharmacological therapies. I also undertake clinical service within the neonatal intensive care unit. In 2013, I moved to become the Chair of a new Department of Pediatric Newborn Medicine at the Brigham and Womens Hospital in Boston. Finally, I have the privilege of mentoring and educating neonatologists and other clinicians in the neurology of the newborn.
Job Titles:
- Member of the Leadership Team
- Member of the Scientific Advisory Board
- FOUNDING SCIENTIST & SAB CHAIR
- Founding Scientist of DeckTherapeutics, Inc
Dr. Richard Deckelbaum is the Founding Scientist of DeckTherapeutics, Inc. and serves as Chair of the Scientific Advisory Board. He is Immediate Past Director of the Institute of Human Nutrition, a Professor of Pediatrics and of Epidemiology, and Robert R. Williams Professor of Nutrition at Columbia University. Dr. Deckelbaum has published over 400 research and other publications, edited a number of books, chaired task forces for the American Heart Association, the European Atherosclerosis Society, the Institute of Medicine, the March of Dimes, and has served on advisory committees of the National Institutes of Health, RAND Corporation, WHO, and the U.S.A. National Academy of Sciences.
Dr. Deckelbaum has held advisory roles relating to clinical applications of lipids with several major nutrition and pharmaceutical companies. He served on the Food and Nutrition Board of the National Academy of Sciences and is a Senior Fellow of the Synergos Institute. Dr. Deckelbaum's laboratory has been funded for over 30 years by NIH and other grants focusing on i.v. lipid emulsions, lipid metabolism, and omega-3 fatty acids. His recent studies have defined the ability of i.v. omega-3 molecules to act acutely via pleiotropic mechanisms in cytoprotection after organ injuries.
Job Titles:
- Member of the Board of Directors
- BOARD OBSERVER
- Co - Founder, Co - Chair, and Co - Manager of the Investment Committee of the Catalytic Impact Foundation
Richard Lipkin is a Co-Founder, Co-Chair, and Co-Manager of the Investment Committee of the Catalytic Impact Foundation (CIF). He is also a Managing Director of Easton Capital Investment Group, a NYC-based life sciences and healthcare venture capital firm; and a Co-Founder and Co-Chair of Princeton Alumni Angels. Through CIF, he also serves as a Board Director of Epivax Therapeutics and Ceretype Neuromedicine.
Previously, he served as a partner of Commerce Health Ventures, a life sciences and healthcare fund of NewSpring Capital; Laird & Company, a private merchant bank; and other private investment partnerships, including as a biotech analyst and consultant for a Goldman Sachs hedge fund.
Lipkin has studied cognitive and computational neuroscience at Columbia University and the Marine Biological Laboratory in Woods Hole, MA, and served on Columbia University Medical Center's Health Sciences Advisory Council, Neuroscience Council, and Medical Science and Technology Council.
He has served as member of boards, councils, and committees for the Weizmann Institute of Science, the Israel Cancer Research Fund, Rockefeller University, Marine Biological Laboratory, Columbia University, the New York Academy of Sciences, and the Montefiore Medical Center. He is an honors graduate of Princeton University, has an MBA from Columbia Business School, and served as a Senior Staff Associate in Columbia University's Zuckerman Institute of Mind, Brain, and Behavior.
Job Titles:
- Member of the Scientific Advisory Board
- Chairman, DEPARTMENT of PEDIATRIC NEWBORN MEDICINE, BRIGHAM and WOMENS HOSPITAL
Job Titles:
- Member of the Board of Directors
- Non - Executive Director